Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...